- -- 12 November 2012
- immatics appoints Peter Chambré as Chairman
- -- 08 November 2012
- immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment and is granted US orphan drug designation by the FDA
- -- 27 September 2012
- IMA950 Phase I results presented by Allan James at ESMO 2012 (Sept. 30) in Vienna
- -- 28 August 2012
- IMA950 data presented by Roy Rampling at EANO 2012 (Sept. 7) in Marseille
- -- 29 July 2012
- immatics announces publication of IMA901 cancer vaccine data in Nature Medicine: immune response associates with longer survival
- -- 01 June 2012
- immatics presents encouraging overall survival data from a phase 2 study in Advanced Colorectal Cancer at the ASCO Annual Meeting
- -- 25 May 2012
- immatics presenting at ASCO Annual Meeting 2012 (June 1-5) in Chicago
- -- 25 May 2012
- immatics wins 2012 TiE50 Award
- -- 22 May 2012
- immatics at CIMT Annual Meeting 2012 starting tomorrow in Mainz, Germany
- -- 03 May 2012
- Harpreet Singh, CSO at immatics, will present at Immunotherapy Leaders’ Forum 2012 (May 9-11) in Barcelona, Spain
- -- 19 April 2012
- Paul Higham, CEO at immatics, will present at BioTrinity 2012 (April 24-26) in Newbury, Berkshire, UK
- -- 12 April 2012
- immatics appoints Dr Rainer Kramer as Chief Business Officer
- -- 01 April 2012
- immatics and collaborators publish preclinical results for Glioma Vaccine IMA950 in "Brain"
- -- 24 January 2012
- immatics presents positive Phase II results with its therapeutic cancer vaccine IMA910 in patients with advanced colorectal cancer at the ASCO Gastrointestinal Cancers Symposium
